The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
caixaresearch
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
“la Caixa” Foundation has subsidized a new transversal platform for next generation single-cell sequencing: UNderstanding cancer through sIngle cell seQUEncing:…
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
In an invited viewpoint article published in the Cancer Discovery, co-authors Elena Garralda, Executive Director of VHIO’s Research Unit for…
In her latest On target column, author Elena Garralda, Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer…
